ACADIA PHARMACEUTICALS INC. (ACAD) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $37.84M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$4.62M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $35.76M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $32.37M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $37.84M | (m) | $307.96M | (m) | $5.09M* | $100.78M* | $28.32M | $81.56M | $160.25M | $14.97M |
| 2026-03-31 | Reported | (m) | -$4.62M | (m) | $268.06M | (m) | $5.21M | $33.98M | $24.79M | $76.87M | $171.02M | $344.00K |
| 2025-09-30 | Reported | (m) | $35.76M | (m) | $278.63M | (m) | $388.00K* | $74.29M* | $21.65M | $87.83M | $133.40M | -$27.18M |
| 2025-06-30 | Reported | (m) | $32.37M | (m) | $264.57M | (m) | $297.00K* | $63.96M* | $20.73M | $77.95M | $133.51M | $13.54M |
| 2025-03-31 | Reported | (m) | $19.29M | (m) | $244.32M | (m) | $0.00 | $20.32M | $20.39M | $78.27M | $126.37M | $8.79M |
| 2024-09-30 | Reported | (m) | $31.64M | (m) | $250.40M | (m) | $70.00K* | $63.25M* | $18.86M | $66.61M | $133.29M | $6.04M |
| 2024-06-30 | Reported | (m) | $30.44M | (m) | $241.96M | (m) | (m) | $25.01M* | $18.23M | $76.23M | $117.06M | $3.79M |
| 2024-03-31 | Reported | (m) | $15.21M | (m) | $205.83M | (m) | (m) | $29.08M | $22.95M | $59.68M | $107.99M | $4.45M |
| 2023-09-30 | Reported | (m) | -$57.78M | (m) | $211.70M | (m) | (m) | -$58.95M* | $14.62M | $156.96M | $97.89M | $13.03M |
| 2023-06-30 | Reported | (m) | $3.04M | (m) | $165.24M | (m) | (m) | $8.20M* | $7.46M | $58.77M | $95.97M | $5.23M |
| 2023-03-31 | Reported | (m) | -$53.58M | (m) | $118.46M | (m) | (m) | -$17.93M | $1.67M | $69.14M | $101.23M | -$1.92M |
| 2022-09-30 | Reported | (m) | -$30.87M | (m) | $130.71M | (m) | $0.00* | -$727.00K* | $2.14M | $81.34M | $78.11M | $768.00K |
| 2022-06-30 | Reported | (m) | -$33.65M | (m) | $134.56M | (m) | $0.00* | -$13.13M* | $2.67M | $75.65M | $89.90M | $443.00K |
| 2022-03-31 | Reported | (m) | -$113.02M | (m) | $115.47M | (m) | $0.00 | -$76.33M | $2.95M | $128.85M | $96.68M | $485.00K |
| 2021-09-30 | Reported | (m) | -$15.30M | (m) | $131.61M | (m) | $0.00* | -$17.06M* | $3.69M | $58.56M | $81.67M | -$332.00K |
| 2021-06-30 | Reported | (m) | -$43.71M | (m) | $115.22M | (m) | $45.00K* | -$25.33M* | $2.53M | $56.94M | $96.79M | $473.00K |
| 2021-03-31 | Reported | (m) | -$66.77M | (m) | $106.55M | (m) | $1.08M | -$60.15M | $2.19M | $56.97M | $111.66M | $21.00K |
| 2020-09-30 | Reported | (m) | -$85.90M | (m) | $120.58M | (m) | $1.72M* | -$22.79M* | $2.00M | $120.08M | $81.59M | -$199.00K |
| 2020-06-30 | Reported | (m) | -$44.01M | (m) | $110.10M | (m) | $2.93M* | -$36.88M* | $2.90M | $64.30M | $84.34M | $393.00K |
| 2020-03-31 | Reported | (m) | -$89.52M | (m) | $90.07M | (m) | $934.00K | -$49.00M | $2.80M | $72.64M | $101.97M | (m) |
| 2019-09-30 | Reported | (m) | -$45.42M | (m) | $94.59M | (m) | $80.00K* | -$18.85M* | $2.42M | $62.62M | $72.70M | -$264.00K |
| 2019-06-30 | Reported | (m) | -$57.09M | (m) | $83.20M | (m) | $20.00K* | -$38.40M* | $2.96M | $67.32M | $67.98M | $365.00K |
| 2019-03-31 | Reported | (m) | -$87.63M | (m) | $62.96M | (m) | $822.00K | -$64.17M | $2.95M | $52.92M | $93.09M | $375.00K |
| 2018-09-30 | Reported | (m) | -$61.27M | (m) | $58.30M | (m) | $1.01M* | -$42.28M* | $3.84M | $53.11M | $61.09M | $376.00K |
| 2018-06-30 | Reported | (m) | -$64.08M | (m) | $57.06M | (m) | $115.00K* | -$40.88M* | $3.56M | $46.59M | $69.47M | $219.00K |
| 2018-03-31 | Reported | (m) | -$54.82M | (m) | $48.87M | (m) | $448.00K | -$45.24M | $2.15M | $39.28M | $60.93M | $647.00K |
| 2017-09-30 | Reported | (m) | -$65.64M | (m) | $35.58M | (m) | $56.00K* | -$58.40M* | $2.13M | $36.42M | $61.59M | $667.00K |
| 2017-06-30 | Reported | (m) | -$68.04M | (m) | $30.48M | (m) | $264.00K* | (m) | $2.22M | $34.18M | $61.13M | $398.00K |
| 2017-03-31 | Reported | (m) | -$88.72M | (m) | (m) | (m) | $485.00K | (m) | (m) | $35.41M | $65.66M | $85.00K |
| 2016-09-30 | Reported | (m) | -$72.40M | (m) | (m) | (m) | $470.00K* | (m) | (m) | $25.81M | $50.53M | (m) |
| 2016-06-30 | Reported | (m) | -$71.92M | (m) | (m) | (m) | $580.00K* | (m) | (m) | $20.48M | $50.77M | (m) |
| 2016-03-31 | Reported | (m) | -$50.26M | (m) | (m) | (m) | $207.00K | (m) | (m) | $22.77M | $27.49M | (m) |
| 2015-09-30 | Reported | (m) | -$39.00M | (m) | (m) | (m) | $186.00K* | (m) | (m) | $18.73M | $20.31M | (m) |
| 2015-06-30 | Reported | (m) | -$39.50M | (m) | (m) | (m) | $674.00K* | (m) | (m) | $18.38M | $21.12M | (m) |
| 2015-03-31 | Reported | (m) | -$40.55M | (m) | (m) | (m) | $988.00K | (m) | (m) | $16.30M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$24.99M | (m) | (m) | (m) | $80.00K* | (m) | (m) | $16.95M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$21.72M | (m) | (m) | (m) | $0.00* | (m) | (m) | $13.80M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$17.96M | (m) | (m) | (m) | $6.00K | (m) | (m) | $11.67M | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$10.81M | (m) | (m) | (m) | $416.00K* | (m) | (m) | $7.25M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$9.16M | (m) | (m) | (m) | (m) | (m) | (m) | $7.11M | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$6.16M | (m) | (m) | (m) | (m) | -$6.58M | (m) | $4.43M | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$2.41M | (m) | (m) | (m) | (m) | -$5.31M* | (m) | $4.40M | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$5.43M | (m) | (m) | (m) | (m) | -$4.80M* | (m) | $4.47M | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$6.23M | (m) | (m) | (m) | (m) | -$5.23M | (m) | $5.02M | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$5.09M | (m) | (m) | (m) | (m) | -$4.17M* | (m) | $4.16M | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$6.58M | (m) | (m) | (m) | (m) | -$5.28M* | (m) | $4.32M | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$5.86M | (m) | (m) | (m) | (m) | -$5.11M | (m) | $4.41M | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$4.24M | (m) | (m) | (m) | (m) | -$2.52M* | (m) | $4.96M | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$4.30M | (m) | (m) | (m) | (m) | (m) | (m) | $5.04M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | $104.81M | (m) | $1.07B | (m) | $4.69M | $109.84M | $89.00M | $328.80M | $548.89M | -$252.10M |
| 2024-12-31 | Reported | (m) | $230.79M | (m) | $957.80M | (m) | $523.00K | $157.72M | $81.84M | $303.25M | $488.43M | $31.62M |
| 2023-12-31 | Reported | (m) | -$73.38M | (m) | $726.44M | (m) | $50.00K | $16.70M | $41.64M | $351.62M | $406.56M | $10.25M |
| 2022-12-31 | Reported | (m) | -$223.60M | (m) | $517.24M | (m) | $0.00 | -$114.03M | $10.17M | $361.57M | $369.09M | $2.53M |
| 2021-12-31 | Reported | (m) | -$170.44M | (m) | $484.14M | (m) | $1.12M | -$125.66M | $19.14M | $239.41M | $396.03M | $351.00K |
| 2020-12-31 | Reported | (m) | -$286.59M | (m) | $441.75M | (m) | $7.59M | -$136.17M | $10.21M | $319.13M | $388.66M | $611.00K |
| 2019-12-31 | Reported | (m) | -$246.54M | (m) | $339.08M | (m) | $1.13M | -$151.13M | $11.34M | $240.38M | $325.64M | $876.00K |
| 2018-12-31 | Reported | (m) | -$247.44M | (m) | $223.81M | (m) | $2.10M | -$167.47M | $12.38M | $187.16M | $265.76M | $1.26M |
| 2017-12-31 | Reported | (m) | -$292.41M | (m) | $124.90M | (m) | $812.00K | -$217.76M | $9.08M | $149.19M | $255.06M | $1.12M |
| 2016-12-31 | Reported | (m) | -$272.81M | (m) | $17.33M | (m) | $1.51M | -$208.41M | (m) | $99.28M | $186.46M | $1.34M |
| 2015-12-31 | Reported | (m) | -$164.61M | (m) | (m) | (m) | $2.14M | (m) | (m) | $73.87M | $88.30M | $330.00K |
| 2014-12-31 | Reported | (m) | -$93.23M | (m) | (m) | (m) | $180.00K | (m) | (m) | $60.60M | $32.75M | $0.00 |
| 2013-12-31 | Reported | (m) | -$38.30M | (m) | (m) | (m) | $618.00K | (m) | (m) | $26.72M | (m) | $0.00 |
| 2012-12-31 | Reported | (m) | -$20.89M | (m) | (m) | (m) | (m) | -$21.63M | (m) | $18.79M | (m) | $0.00 |
| 2011-12-31 | Reported | (m) | -$22.85M | (m) | (m) | (m) | $3.00K | -$19.90M | (m) | $17.31M | (m) | $17.00K |
| 2010-12-31 | Reported | (m) | $15.09M | (m) | (m) | (m) | (m) | -$10.70M | (m) | $20.58M | (m) | $12.00K |
| 2009-12-31 | Reported | (m) | -$45.47M | (m) | (m) | (m) | (m) | -$13.73M | (m) | $41.59M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |